In early 2015, a Philadelphia jury had passed a verdict of $2.5 million in damages to be paid to a Risperdal plaintiff which was also the first verdict for the antipsychotic drug Risperdal's alleged side effect of abnormal breast growth in males, stating that the defendant failed to warn about the risks involved. Following this, the defendant, J&J's Janssen Pharmaceutical's, filed a motion seeking a new trial which was upheld by a judge in Philadelphia. Most of the Risperdal cases are pending in the Philadelphia Court of Common Pleas in Pennsylvania, where a small group of cases is being heard as a part of bellwether trial process. In a few cases, settlements have been reached. At least 13,800 Risperdal lawsuits are filed against J&J nationwide.
